vyalev

Vyalev is a fixed-dose combination drug containing the prodrugs foscarbidopa and foslevodopa. It is indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. Both components are administered as a continuous 24-hour subcutaneous infusion using a wearable pump (Vyafuser). Foscarbidopa is converted in vivo to carbidopa, an aromatic amino acid decarboxylase inhibitor that prevents peripheral breakdown of levodopa. Foslevodopa is converted to levodopa, which crosses the blood-brain barrier and is then metabolized to dopamine in the brain. This dual mechanism increases central dopamine levels while minimizing peripheral side effects by reducing systemic conversion of levodopa to dopamine before it reaches the brain. Vyalev was developed as an alternative to oral or intestinal gel formulations of carbidopa/levodopa, offering more stable plasma concentrations and improved control over motor symptoms for patients with advanced disease[1][2][3][4][8][10].

Brand names

VyalexProduodopa

Other names

foscarbidopa and foslevodopafoscarbidopa/foslevodopa